By John Vandermosten, CFA
READ THE FULL ATRS RESEARCH REPORT
The last week of November was a good one for Antares Pharma, Inc. (ATRS) with both Epi Pen and Xyosted now commercially available. These make the second and third approved and commercialized products this year for the company, following Makena in February.
Teva Pharmaceuticals (TEVA) announced on November 27th that the recently approved AB-rated generic Epinephrine Pen is now available in the United States. For the remainder of 2018, only the Epi Pen 0.3 mg version will be available in limited quantities with additional supply of the 0.3 mg version and Epi Pen Jr (0.15 mg) to be available in 2019. The Israeli generic drug manufacturer noted that the Wholesale Acquisition Cost (WAC) will be set at $300, matching Mylan’s (MYL) authorized generic price. Mylan began to suffer shortages in 2017 following an FDA inspection at the Pfizer (PFE) plant where they were manufactured, which has continued to date. We expect that this has created pent up demand for the product that should allow Teva to dispense the entirety of the limited quantities that are now available. We further expect additional device sales at Antares to begin shortly as Teva works through existing inventory and royalties to appear in 2019, with a one-quarter delay.
On Thursday, Antares had more good news publicizing the commercial availability of Xyosted QuickShot auto injector. Xyosted is available in three dosages: 50 mg, 75 mg and 100 mg. Sales reps have been hired and are now in training and should be available in the coming weeks to begin physician and institutional communications. Cross training with the Otrexup sales team should increase efficiencies and market penetration and all Antares sales reps should be able to commercialize both products in the Antares portfolio.
We update our valuation to reflect the commercial availability of Epi Pen and Xyosted and roll forward our DCF model to 2019. This increases our target price from $5.00 per share to $6.00 per share. Antares has benefitted from a number of favorable catalysts in 2018 including the approval and launch of Makena in the first quarter and now Epi Pen and Xyosted in the fourth quarter. We anticipate similarly positive news in 2019 for teriparatide. We also note the development portfolio, including the rescue pen project with Pfizer which provides additional catalysts in the years to come and additional upside to our estimates when details emerge.
Despite a CRL last year, Antares has benefitted from three product approvals and related sales in 2018. The company has also sharpened its focus, divesting its ZomaJet asset and using capital from this sale to pursue new opportunities including the arrangement with Pfizer. Based on the commercialization of Epi Pen and Xyosted and the roll forward of our DCF model, we increase our target price to $6.00 per share.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.
By John Vandermosten, CFA